Kevin Lobo

Director Kevin Lobo purchases 10,000 shares of GEHC at $64.18; stock down 28.5% from 52-week high of $89.77

Kevin Lobo, a Director at GE HealthCare Technologies Inc., purchased 10,000 shares at $64.18 on 2026-05-22, increasing his holdings from 4,363 shares to 14,363 shares (+229.2% net change). The transaction occurred at a price 28.5% below the 52-week high of $89.77, within a 52-week range of $58.75–$89.77, and follows a 23.6% decline over the prior 90 days. The company's fundamentals remain solid with $5.1B in quarterly revenue, $389.0M net income, and a P/E of 15.28. However, Lobo's cross-ticker track record shows a 0.00% well-timed rate on 7 prior open-market sells (average 90d return +8.2%), indicating his historical sales have not preceded declines. The purchase's significance is moderated by the absence of any structural flag indicating this is a discretionary conviction-driven buy versus a routine portfolio action.

Stryker CEO Kevin Lobo sells 57.3K shares (57,313 shares) for $21,131,479.29 across 3 transactions on 2024-11-07

Lobo executed 3 separate sales totaling 57,313 shares for $21,131,479.29 at an average price of $368.70, reducing his holdings by 36.4% from 157.3K to 100.0K shares. The sale occurred as the stock trades near its 52-week high of $375.96 with strong recent momentum (30-day: +6.2%, 90-day: +14.7%), and his prior 4 sales at SYK in November 2023 all saw the stock rise over the subsequent 90 days (range +20.3% to +21.4%), meaning none were well-timed. The company remains fundamentally strong with $5.5B quarterly revenue, +11.1% annual growth, and $834.0M net income, though valued at a rich 39.91 P/E. The magnitude and timing of this large open-market sale merit observation against the company's current valuation and recent price strength.